Therapeutic vaccination of SIV-infected, ART-treated infant rhesus macaques using Ad48/MVA in combination with TLR-7 stimulation
Fig 5
Humoral response measured by ELISA and BAMA to therapeutic vaccination in SIV-infected, ART-treated infant RMs.
SIV-specific antibodies directed against gp120 from (A) vaccine strain, SIVsmE543, and (B) challenge strain, SIVmac251, were quantified by binding ELISA area under the curve (AUC) at week 4 prior to ART initiation, week 22 prior to vaccination, week 34 after priming with two doses of Ad48, week 52 after boosting with two doses of MVA, and week 62 prior to analytical treatment interruption (ATI) in TV+TLR7 RMs and equivalent time points for controls. (C) SIV-specific antibodies directed against SIVmac239 gp120, p27, and Nef were measured by Binding Antibody Multiplex Assay (BAMA) at same time points described above. Experimental groups were compared using a two-sided Mann-Whitney test and timepoints within groups were compared using the non-parametric Friedman test with Dunn's multiple comparison test to correct for multiple comparisons (P < 0.05 was considered significant).